Patrick Campbell

Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

A study found omega-3 supplements and a Mediterranean diet improved acne severity and quality of life in patients without prescription meds.

Promoting adherence to a Mediterranean diet in children improves cardiometabolic health biomarkers, according to a new study.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

Study finds women with familial hypercholesterolemia receive less intensive treatment and are less likely to achieve LDL-C goals than men.

An analysis of CLEAR Outcomes and CTTC data suggest bempedoic acid holds its own relative to statin therapy for cardiovascular risk reduction normalized to 1 mmol/L reduction in LDL-C.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

A study of 18,000 patients showed tirzepatide (Mounjaro) led to more significant weight loss than semaglutide (Ozempic) in adults with overweight or obesity.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.

Our dermatology FDA recap for the first half of 2024 includes our top 5 approvals, 3 decisions to watch in the second half of 2024, and a podcast episode with James Del Rosso, DO

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.

Mirum Pharmaceuticals submitted an NDA for chenodiol tablets to treat CTX based on positive phase 3 RESTORE trial results.

Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.

Aquestive Therapeutics announced positive topline data from the trial on June 25, 2024.

The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.

The CATALYST trial sheds light on the true prevalence of hypercortisolism among difficult-to-control type 2 diabetes, with data at ADA 2024 shedding light on adrenal abnormalities and presence among subgroups.

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.